| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/01/2004 | WO2003103613A3 Induction of insulin expression |
| 04/01/2004 | WO2003102131A3 Nucleic acid mediated disruption of hiv fusogenic peptide interactions |
| 04/01/2004 | WO2003100436A3 Diagnostics and therapeutics for diseases associated with chemokine receptor 10 (ccr10) |
| 04/01/2004 | WO2003100093A3 Method of selecting targets for gene silencing by rna interference |
| 04/01/2004 | WO2003099868B1 Method for obtaining anti-idiotype antibodies |
| 04/01/2004 | WO2003099830A3 Cardiolipin compositions, methods of preparation and use |
| 04/01/2004 | WO2003096022A3 Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xl and bcl-w proteins |
| 04/01/2004 | WO2003095476A3 PEPTIDES FOR REGULATION OF UROKINASE (uPA) AND TISSUE TYPE (tPA) PLASMINOGEN ACTIVATOR AND METHOD OF OPTIMIZING THERAPEUTIC EFFICACY |
| 04/01/2004 | WO2003092718A3 Treatment and inhibition of ocular infections and wounds by cap37 and cap37 peptides |
| 04/01/2004 | WO2003089934A3 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1/lap-1 |
| 04/01/2004 | WO2003087840A3 Protein involved in cancer |
| 04/01/2004 | WO2003086491B1 Tissue defect dressings comprising a keratin network |
| 04/01/2004 | WO2003086452A3 Methods of enhancing lysosomal storage disease therapy |
| 04/01/2004 | WO2003086320A3 Use of resistin to treat hematopoietic disorders |
| 04/01/2004 | WO2003084566A3 Proteins involved in the regulation of energy homeostasis |
| 04/01/2004 | WO2003084343A3 Method and dietary composition for improving fat digestibility |
| 04/01/2004 | WO2003082926A3 Antimicrobial polymer conjugates |
| 04/01/2004 | WO2003082314A3 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| 04/01/2004 | WO2003081238A3 Cytocapacity test |
| 04/01/2004 | WO2003080663A3 Tenascin-w compositions and uses thereof |
| 04/01/2004 | WO2003078602A3 Methods of expressing non-endogenous g protein coupled receptors in cells |
| 04/01/2004 | WO2003077865A3 Methods and compositions for directing cells to target organs |
| 04/01/2004 | WO2003077864A3 Methods and compositions for directing cells to target organs |
| 04/01/2004 | WO2003075953A3 Immunomodulatory polymeric antigens for treating inflammatory pathogies |
| 04/01/2004 | WO2003075834A3 Activated protein c formulations |
| 04/01/2004 | WO2003074078A3 Cg3842 homologous proteins involved in the regulation of energy homeostasis |
| 04/01/2004 | WO2003074022A3 Emulsion containing hydrophobic nanodrops with bound hemoglobin molecules in a hydrophilic phase as a blood substitute |
| 04/01/2004 | WO2003072029A3 Methods of extending corneal graft survival |
| 04/01/2004 | WO2003070888A3 Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid |
| 04/01/2004 | WO2003070886A3 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
| 04/01/2004 | WO2003070749A3 Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
| 04/01/2004 | WO2003066877A3 Compositions and methods relating to hepatic specific genes and proteins |
| 04/01/2004 | WO2003066088A3 Protease screening and novel use of proteases |
| 04/01/2004 | WO2003063792A3 Compositions and methods related to tim-3, a th1-specific cell surface molecule |
| 04/01/2004 | WO2003060090A3 Novel cytokine zcytor17 ligand |
| 04/01/2004 | WO2003057012A8 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| 04/01/2004 | WO2003054146A3 Self-assembly and mineralization of peptide-amphiphile nanofibers |
| 04/01/2004 | WO2003038050A3 Antisense modulation of phospholipase a2 group v expression |
| 04/01/2004 | WO2003031940A3 Structural and cytoskeleton-associated proteins |
| 04/01/2004 | WO2003029429A3 Traversal of nucleic acid molecules through a fluid space and expression in repair cells |
| 04/01/2004 | WO2003029282A3 Tumor-peptide antigens from the human prdi-bf1-protein |
| 04/01/2004 | WO2003026635A3 Improved method of treating the syndrome of type 2 diabetes in humans |
| 04/01/2004 | WO2003012065A3 Kinases and phosphatases |
| 04/01/2004 | WO2003012044A9 Hagfish cathelin-associated antimicrobial peptides and genes |
| 04/01/2004 | WO2003007845A9 Dry hemostatic compositions and methods for their preparation |
| 04/01/2004 | WO2003000707A8 Antisense modulation of superoxide dismutase 1, soluble expression |
| 04/01/2004 | WO2002092758A3 Gastrokines and derived peptides including inhibitors |
| 04/01/2004 | WO2002089856A8 Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery |
| 04/01/2004 | WO2002085286A3 Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals |
| 04/01/2004 | WO2002077180A3 Novel nucleic acids and polypeptides |
| 04/01/2004 | WO2002070676A9 Use of protein histidine phosphatase |
| 04/01/2004 | WO2002064131A3 Inflammation-inhibiting compounds |
| 04/01/2004 | WO2002058637A9 Compositions and methods for diagnosis of neuropsychiatric disorders |
| 04/01/2004 | WO2002057299A9 Vegfr-3 binding peptides and their use for inhibiting angiogenesis |
| 04/01/2004 | WO2002043654A8 Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions |
| 04/01/2004 | WO1990001943A8 Treatment of myeloid leukemias by inducing terminal differentiation with interleukin-6 |
| 04/01/2004 | US20040063922 Ester interchange; autocatalyst; genetic engineering; gene therapy for genetic disorders |
| 04/01/2004 | US20040063921 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/01/2004 | US20040063917 Modified erythropoietin (epo) with reduced immunogenicity |
| 04/01/2004 | US20040063916 Bactericides; antibiotics |
| 04/01/2004 | US20040063910 Comprises cytokine fusion protein receptor domain for diagnosis and treatment of cell proliferative and vision disorders |
| 04/01/2004 | US20040063909 Comprises nucleotide sequences coding membrane proteins for treatment and diagnosis cell proliferative, inflammatory, autoimmune and nervous system disorders |
| 04/01/2004 | US20040063908 Comprises genetically engineered hemophilus adherence and penetration (HAP) proteins for treatment and prevention of influenza; immunotherapy |
| 04/01/2004 | US20040063907 Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 04/01/2004 | US20040063906 Peptide nucleic acid sequences; antibodies for controlling disease; bactericides, viricides |
| 04/01/2004 | US20040063905 Armed peptides |
| 04/01/2004 | US20040063904 Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
| 04/01/2004 | US20040063903 Wound healing agents; anticoagulants |
| 04/01/2004 | US20040063790 By administering an organic peptidomimetic vibronectin receptor alpha v beta 3 antagonist of given structures |
| 04/01/2004 | US20040063747 Local anesthetic methods and kits |
| 04/01/2004 | US20040063742 Such as 5-(4-Chlorophenyl)-8-methyl-6,7,8,9-tetrahydro-1-H-pyrrolo(3.2-h)isoquinoline-2,3-dione-3-oxime-(phenyl))urea; kits; drug screening |
| 04/01/2004 | US20040063700 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 04/01/2004 | US20040063697 Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 04/01/2004 | US20040063657 Antisense modulation of phosphoinositide-3-kinase, regulatory subunit 4, P150 expression |
| 04/01/2004 | US20040063655 Antisense modulation of transforming growth factor-beta expression |
| 04/01/2004 | US20040063652 Introducing multiple nucleic acid molecules simultaneously without deletereous effects; controlling level of expression |
| 04/01/2004 | US20040063645 Such as ((2-(3-guanidino-2-hydroxy-propylcarbamoyl)-1H-indol-5-yl)-amide) |
| 04/01/2004 | US20040063642 Novel benzimidazolone peptidomimetics as thrombin receptor antagonists |
| 04/01/2004 | US20040063641 Healing fractures in distractive osteogenesis; accelerating regeneration and consolidation; torsional and mechanical stiffness; mass |
| 04/01/2004 | US20040063640 Inhibitor of glutathione s-transferase; anticancer agents |
| 04/01/2004 | US20040063639 Storage stable buffered liquid and lyophilized materials |
| 04/01/2004 | US20040063638 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/01/2004 | US20040063637 Aqueous formulation of fusion inhibitor and polyol; minimizes number of injections and site reaction |
| 04/01/2004 | US20040063636 Use of compounds for the regulation of food intake |
| 04/01/2004 | US20040063635 Recombinant human albumin fusion proteins with long-lasting biological effects |
| 04/01/2004 | US20040063634 Modified kertinocyte growth factor (kgf) with reduced immunogenicity |
| 04/01/2004 | US20040063633 Interleukin-18 inducing agent |
| 04/01/2004 | US20040063632 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 04/01/2004 | US20040063631 Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu amino acid sequence |
| 04/01/2004 | US20040063630 Enhanced diuresis with reduced side effects; recombinant or synthetic human B-type peptide |
| 04/01/2004 | US20040063629 Treatment of damaged connective tissue |
| 04/01/2004 | US20040063627 Stabilizing dystrophin associated protein complexes; abnormal synapses or neuromuscular junction disorders |
| 04/01/2004 | US20040063626 Use of cyclosporin a 7-thioamide derivatives for hair growth |
| 04/01/2004 | US20040063625 Cyclic peptide |
| 04/01/2004 | US20040063624 Method of inhibiting the transition of free HIV virus through the cllular mucosal barrier |
| 04/01/2004 | US20040063623 Formulation of boronic acid compounds |
| 04/01/2004 | US20040063621 Heterocarpine, a human ghrh-binding protein |
| 04/01/2004 | US20040063619 Delivery system for heparin-binding growth factors |
| 04/01/2004 | US20040063618 Peptide nucleic acids having improved uptake and tissue distribution |
| 04/01/2004 | US20040063615 For therapy of diabetes |